Recombinant factor VIIA is used in a Jehova's Witness with liver cirrhosis to correct prothrombin time, bleeding time, and thromboelastographic parameters, enabling safe percutaneous injection of hepatocellular carcinoma

Recombinant factor VIIA is used in a Jehova's Witness with liver cirrhosis to correct prothrombin time, bleeding time, and thromboelastographic parameters, enabling safe percutaneous injection of hepatocellular carcinoma

Bibliographic Details
Main Authors:	Papatheodoridis, G, Chung, S, Keshav, S, Hardaker, L, Pasi, J, Burroughs, A
Format:	Journal article
Published:	1999

Similar Items

Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis.
by: Papatheodoridis, G, et al.
Published: (1999)

Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis
by: Papatheodoridis, G, et al.
Published: (1999)

Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope
by: Xingshun Qi, et al.
Published: (2017-01-01)

Prothrombine and activated partial thromboplastin time are prolonged in hepatic cirrhosis
by: Edward Kurnia Setiawan Limijadi, et al.
Published: (2016-05-01)

Resection of Large Urological Tumors With or Without Inferior Vena Cava Extension in Jehova's Witnesses
by: Gaetano Ciancio, et al.
Published: (2020-12-01)

Low-dose recombinant factor VIIa for massive bleeding
by: A Mordasini, et al.
Published: (2011-07-01)

Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article
by: Pall T. Onundarson, et al.
Published: (2021-10-01)

Hemostatic and thromboelastographic parameters in dogs with renal azotemia
by: Hendryk Fischer, et al.
Published: (2023-06-01)

Plasma prothrombin time and activated partial thromboplastin time as predictors of bleeding manifestations during dengue hemorrhagic fever
by: I. N. Budastra, et al.
Published: (2009-04-01)

The progress of prothrombin time measurement
by: Juha Eero Horsti
Published: (2009-12-01)

Prothrombin time in retinitis pigmentosa
by: Vinchurkar Manisha
Published: (1998-01-01)

Prothrombin Complex Concentrates in Life-Threatening Bleeding
by: Mustafa Burak Sayhan, et al.
Published: (2016-12-01)

Thromboelastographic evaluation of coagulation in a dog with anticoagulant rodenticide intoxication
by: ERALP İNAN O, et al.
Published: (2016-05-01)

Thromboelastographic evaluation of coagulation profile in dogs with subclinical and clinical ehrlichiosis
by: Meriç KOCATÜRK, et al.
Published: (2023-07-01)

Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
by: Bettina Schenk, et al.
Published: (2018-01-01)

Use of Recombinant Factor VIIa in Gastrointestinal Bleeding in Children with Malignancies: A Case Series
by: Jan Hau Lee MBBS, MRCPCH, et al.
Published: (2010-06-01)

CORRELATION BETWEEN PROTHROMBIN TIME LEVELS OBTAINED USING PROTHROMBIN METER WITH LABORATORY IN NEONATES
by: Usman Shakil, et al.
Published: (2019-10-01)

Thromboelastographic study of fibrin clot and molecular basis of maximum clot firmness
by: D. S. Korolova, et al.
Published: (2021-04-01)

Analysis of the timing of endoscopic treatment for esophagogastric variceal bleeding in cirrhosis
by: Kaini Wu, et al.
Published: (2022-12-01)

Use of recombinant factor VIIa in the treatment of massive retroperitoneal bleeding due to severe necrotizing pancreatitis
by: Stefanović Branislav, et al.
Published: (2009-01-01)

Die Zeugen Jehovas und das Datenschutzrecht
by: Thomas Hoeren

Evaluation of the effect of etamsylate on thromboelastographic traces of canine blood with and without the addition of heparin
by: Vicente Herrería-Bustillo, et al.
Published: (2023-12-01)

Specific parameters of the thromboelastographic profile of patients with COVID-19 in the intensive care unit
by: A. V. Samorodov, et al.
Published: (2020-12-01)

Thromboelastographic Evaluation in Patients with Severe Sepsis or Septic Shock: A Preliminary Analysis
by: Sokyung Yoon, et al.
Published: (2020-07-01)

Thromboelastographic analysis of novel polyethylene glycol based low volume resuscitation solutions.
by: Loren K Liebrecht, et al.
Published: (2018-01-01)

Prothrombin time and activated partial thromboplastin time in women with gestational diabetes mellitus
by: Samira Mahjabeen, et al.
Published: (2023-01-01)

Intravenous Vitamin K1 for the Correction of Prolonged Prothrombin Times in Non-Bleeding Critically Ill Patients: A Prospective Observational Study
by: Sofia Dahlberg, et al.
Published: (2021-07-01)

Case report of recurrent bleeding in an infant with isolated prolonged prothrombin time due to congenital factor VII deficiency---a riddle solved
by: Mimi Ganguly, et al.
Published: (2022-01-01)

Jehovas Vidner. I grænsefladen af den danske religionsmodel
by: Annika Hvithamar
Published: (2015-11-01)

Enfrentamiento médico legal del paciente testigo de jehová
by: Dr. G. Marco Guerrero
Published: (2011-05-01)

Jehova gleich Moloch: Eine »antireligiöse« Lesart von Salammbô
by: Agnès Bouvier
Published: (2012-06-01)

Should we Test the Prothrombin Time in Anticoagulated Epistaxis Patients?
by: Michael B. Soyka M.D., et al.
Published: (2013-03-01)

Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time
by: Junwoo Bae, et al.
Published: (2019-05-01)

RECOMBINANT FACTOR VIIa – NEW TREATMENT OPTION FOR CONTROL OF INTRACTABLE BLEEDING IN SURGICAL AND TRAUMA PATIENTS AND IN OTHER HAEMOSTASIS DISORDERS
by: Samo Zver, et al.
Published: (2004-12-01)

Overview of the use of recombinant factor VIIa in children
by: Puetz J
Published: (2014-10-01)

Effect of higher centrifugation speed and shortened centrifugation time on prothrombin and activated thromboplastin time
by: Azlin I,, et al.
Published: (2011)

Montoya witness of this time. Memorials.
by: María Isabel Artigas
Published: (2016-12-01)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
by: Siddharth Mehrotra, et al.
Published: (2022-12-01)

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
by: Maureane Hoffman, et al.
Published: (2018-12-01)

Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
by: Egon Persson, et al.
Published: (2019-10-01)